Skip to Main Content

The Food and Drug Administration has declined to grant emergency use authorization to lenzilumab, an experimental drug developed by Humanigen, for the treatment of hospitalized patients with Covid-19, the company said Thursday.

“In its letter, FDA stated that it was unable to conclude that the known and potential benefits of lenzilumab outweigh the known and potential risks of its use as a treatment for COVID-19,” Humanigen said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment